A Phase 1 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 84 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 13th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 22 in phase 1, and was the 113th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 114 · Phase 3 11 · Phase 4 3
First in 1988; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 49 across the 145 interventional studies. Of the 132 that completed or were terminated, 77 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 155 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2011, is one of 8 in phase 1, and was the 20th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
4 of the studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00466531Memorial Sloan Kettering Cancer CenterTreatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | 2026-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This randomized, parallel-group, multi-center study will compare the pharmacokinetics and safety of subcutaneous administration of MabThera (rituximab) versus intravenous MabThera in combination with chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL). The study consists of 2 parts. In part 1, patients who have previously received 4 cycles of intravenous MabThera will receive in Cycle 5 intravenous MabThera and in Cycle 6 subcutaneous MabThera. In part 2, patients will be randomized to receive either 6 cycles of intravenous MabThera, or 1 cycle of intravenous MabThera and 5 cycles of subcutaneous MabThera. Additionally, all patients will receive chemotherapy (fludarabine and cyclophosphamide) on Days 1-3 or Days 1-5 of every cycle. The anticipated time on study drug is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusion criterion for Part 1:
Additional exclusion criterion for Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]
Days 1-3 or Days 1-5 of cycles 1-6
Days 1-3 or Days 1-5 of cycles 1-6
One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
6 cycles of intravenous MabThera
Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab
Ctrough is defined as the trough or minimum serum concentration. Pharmacokinetic parameters for rituximab were assessed during Cycles 5 (IV rituximab) and 6 (SC rituximab). Rituximab pharmacokinetic (PK) data from Part 1 were integrated into a population PK model using parametric, nonlinear, mixed-effects modelling. Rituximab IV 500 mg/m\^2 administered once every 4 weeks was compared to fixed doses of rituximab SC between 1400 mg and 1870 mg. The dose selection was performed on Ctrough concentrations at Cycle 5 (pre-dose Cycle 6). A test of the probability of success was applied to each of the 100 replicates, and the percentage of replicates with a positive test corresponded to the probability of success of the trial.
Time frame: Pre-dose and post-dose (15 minutes to end of infusion) on Day 1 and on Days 2, 5, 11 and 15 of Cycle 5 and Pre-dose, Post-dose on Days 2, 3, 5,11, 15 and 29 of Cycle 6; Pre-dose was taken 2 hours prior rituximab dose
Part 2: Rituximab C Trough Levels at Cycle 5
Ctrough is defined as the trough or minimum serum concentration in a given cycle of treatment. The objective of Part 2 was to demonstrate the comparability of the observed Ctrough of rituximab SC 1600 mg and rituximab IV 500 mg/m2 at Cycle 5, as assessed by a non-inferiority test with a lower boundary of at least 0.8 for the 90% CI.
Time frame: +/- 25hours around the 28th day post the 5th Cycle of Rituximab administration
Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6
AUC values were calculated by numerical integration using the linear trapezoidal rule. AUC levels were analyzed using the model below: Ln(AUC) = μ + τi + BlTLij + εij wherein, Ln is the natural log, μ denotes the overall mean effect, τi the effect in each treatment group, BlTLij the tumor load at baseline for each patient and εij a random error variable with normal distribution and mean 0. The treatment effect therein was based on a contrast statement in the model to calculate 90 % confidence intervals for ln(AUC SC)- ln(AUC IV).
Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6
Cmax was obtained directly from the measured concentration-time curves. The concentration-time curve is the result of time points of blood sampling and its measured concentration of rituximab in the blood samplings.
Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6
Multiple blood samples were obtained at pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab IV arm, and at pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab SC arm and time to peak plasma concentration of rituximab was determined.
Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Part 2: Terminal Half-Life of Rituximab at Cycle 6
The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.
Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration
In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC
Time frame: Days 4 to 5 in Cycle 6
Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV
Physicians and nurses who administered rituximab were asked to answer the following question: " If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones)". The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.
Time frame: Days 4-5 in Cycle 6
Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV
Physicians and nurses who administered rituximab were asked to answer the following question: "Which formulation of rituximab (SC or IV) do you think is more convenient?" with pre-specified responses as below. Percentage of participants with specified answers were reported. The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.
Time frame: Days 4-5 in Cycle 6
Part 1: Percentage of Participants With Anti-Rituximab Antibodies
Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.
Time frame: Predose at Cycles 5 and 6 and at each follow up visit until 24 months after the last dose
Part 2: Percentage of Participants With Anti-Rituximab Antibodies
In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.
Time frame: Day 0 of Cycle 1 and Day 1 of Cycles 1, 2, 3, 4, 5, and 6 and at each follow-up visit until 24 months after the last dose of rituximab.
Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit
CD 19 is a surface antigen (protein) present on B-lymphocytes.
Time frame: Day 1 of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15,18, 21 and 24
Part 1: Percentage of Participants With Total B-Cell Depletion by Visit
Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
Time frame: Day 1 pre-dose of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15, 18, 21 and 24
Part 2: Total CD19+ B-Cell Counts by Visit
CD 19 is a surface antigen (protein) present on B-lymphocytes.
Time frame: Cycle 1 pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 pre-dose in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit
Part 2: Percentage of Participants With Total B-Cell Depletion by Visit
Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
Time frame: Cycle 1 Pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit
| Milestone | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|
| Started | 16 | 17 | 23 | 8 | 0 | 0 |
| Completed | 16 | 17 | 23 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 8 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|
| Started | 16 | 17 | 23 | 8 | 0 | 0 |
| Completed | 10 | 10 | 17 | 7 | 0 | 0 |
| Not completed | 6 | 7 | 6 | 1 | 0 | 0 |
| Withdrew: Death | 3 | 1 | 3 | 1 | 0 | 0 |
| Withdrew: Disease progression | 3 | 6 | 3 | 0 | 0 | 0 |
| Milestone | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 88 | 88 |
| Completed | 0 | 0 | 0 | 0 | 72 | 73 |
| Not completed | 0 | 0 | 0 | 0 | 16 | 15 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawn prior to treatment | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 7 | 9 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 |
| Milestone | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 87 | 87 |
| Completed | 0 | 0 | 0 | 0 | 68 | 75 |
| Not completed | 0 | 0 | 0 | 0 | 19 | 12 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 6 | 3 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 5 | 5 |
| Withdrew: Noncompliance | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 2 |
| Milestone | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|
| Started | 16 | 17 | 23 | 8 | 88 | 88 |
| Completed | 13 | 16 | 20 | 7 | 72 | 78 |
| Not completed | 3 | 1 | 3 | 1 | 16 | 10 |
| Withdrew: Death | 3 | 1 | 3 | 1 | 16 | 10 |
Ctrough is defined as the trough or minimum serum concentration. Pharmacokinetic parameters for rituximab were assessed during Cycles 5 (IV rituximab) and 6 (SC rituximab). Rituximab pharmacokinetic (PK) data from Part 1 were integrated into a population PK model using parametric, nonlinear, mixed-effects modelling. Rituximab IV 500 mg/m\^2 administered once every 4 weeks was compared to fixed doses of rituximab SC between 1400 mg and 1870 mg. The dose selection was performed on Ctrough concentrations at Cycle 5 (pre-dose Cycle 6). A test of the probability of success was applied to each of the 100 replicates, and the percentage of replicates with a positive test corresponded to the probability of success of the trial.
| mg | Part 1: Rituximab SC |
|---|---|
| Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab | 1600 |
Ctrough is defined as the trough or minimum serum concentration in a given cycle of treatment. The objective of Part 2 was to demonstrate the comparability of the observed Ctrough of rituximab SC 1600 mg and rituximab IV 500 mg/m2 at Cycle 5, as assessed by a non-inferiority test with a lower boundary of at least 0.8 for the 90% CI.
| μg/mL | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Part 2: Rituximab C Trough Levels at Cycle 5 | 61.50 ± 89.54 | 97.53 ± 55.27 |
AUC values were calculated by numerical integration using the linear trapezoidal rule. AUC levels were analyzed using the model below: Ln(AUC) = μ + τi + BlTLij + εij wherein, Ln is the natural log, μ denotes the overall mean effect, τi the effect in each treatment group, BlTLij the tumor load at baseline for each patient and εij a random error variable with normal distribution and mean 0. The treatment effect therein was based on a contrast statement in the model to calculate 90 % confidence intervals for ln(AUC SC)- ln(AUC IV).
| μg*day/mL | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6 | 3630.43 ± 38.61 | 4088.78 ± 37.52 |
Cmax was obtained directly from the measured concentration-time curves. The concentration-time curve is the result of time points of blood sampling and its measured concentration of rituximab in the blood samplings.
| μg/mL | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6 | 279.78 ± 23.96 | 202.16 ± 36.10 |
Multiple blood samples were obtained at pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab IV arm, and at pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab SC arm and time to peak plasma concentration of rituximab was determined.
| days | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6 | 0.22 ± 130.84 | 3.14 ± 87.62 |
The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.
| days | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Part 2: Terminal Half-Life of Rituximab at Cycle 6 | 30.09 ± 41.86 | 30.71 ± 33.19 |
In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC
| percentage of participants or nurses | Part 1: Rituximab SC 1400 mg | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg |
|---|---|---|---|
| Participants who preferred SC | 88.0 | 100.0 | 91.0 |
| Participants who preferred IV | 13.0 | 0.0 | 9.0 |
| Nurses who preferred SC | 88.0 | 100.0 | 91.0 |
| Nurses who preferred IV | 13.0 | 0.0 | 9.0 |
Physicians and nurses who administered rituximab were asked to answer the following question: " If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones)". The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.
| percentage of participants in the survey | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Nurse: 4 or more hours | 21.0 | 21.0 |
| Nurse: At least 3 hours but less than 4 hours | 23.0 | 29.0 |
| Nurse: At least 2 hours but less than 3 hours | 26.0 | 23.0 |
| Nurse: At least 1 hour but less than 2 hours | 17.0 | 11.0 |
| Nurse: Less than 1 hour | 13.0 | 16.0 |
| Physician: 4 or more hours | 21.0 | 22.0 |
| Physician: At least 3 hours but less than 4 hours | 18.0 | 21.0 |
| Physician: At least 2 hours but less than 3 hours | 24.0 | 26.0 |
| Physician: At least 1 hour but less than 2 hours | 22.0 | 19.0 |
| Physician: Less than 1 hour | 10.0 | 7.0 |
Physicians and nurses who administered rituximab were asked to answer the following question: "Which formulation of rituximab (SC or IV) do you think is more convenient?" with pre-specified responses as below. Percentage of participants with specified answers were reported. The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.
| percentage of participants in the survey | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Nurse: Rituximab SC is much more convenient | 81.0 | 77.0 |
| Nurse: Rituximab SC is a little more convenient | 7.0 | 9.0 |
| Nurse: Both formulations are equally convenient | 9.0 | 4.0 |
| Nurse: Rituximab IV is a little more convenient | 3.0 | 10.0 |
| Nurse: Rituximab IV is much more convenient | 0.0 | 0.0 |
| Physician: Rituximab SC is much more convenient | 78.0 | 80.0 |
| Physician: Rituximab SC a little more convenient | 15.0 | 14.0 |
| Physician: Both formulations equally convenient | 6.0 | 6.0 |
| Physician: Rituximab IV a little more convenient | 0.0 | 0.0 |
| Physician: Rituximab IV is much more convenient | 0.0 | 0.0 |
Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.
| percentage of participants | Part 1: Rituximab SC |
|---|---|
| Pre-Dose Cycle 5: positive for HACAs (n=59) | 0.0 |
| Pre-Dose Cycle 5: negative for HACAs (n=59) | 100.0 |
| Post-Dose: positive for HACAs (n=61) | 5.0 |
| Post-Dose: negative for HACAs (n=61) | 95.1 |
In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.
| percentage of participants | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Baseline pre Cycle 1: positive for HACAs (n=87,85) | 0.0 | 2.4 |
| Baseline pre Cycle 1: negative for HACAs (n=87,85) | 100.0 | 97.6 |
| Post-Baseline: positive for HACAs (n=89,85) | 15.0 | 12.0 |
| Post-Baseline: negative for HACAs (n=89,85) | 85.0 | 88.0 |
CD 19 is a surface antigen (protein) present on B-lymphocytes.
| cells per microliter (cells/μL) | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: Rituximab SC 1000 mg | Part 1: No SC Dose Received |
|---|---|---|---|---|---|
| Cycle 5 Day 1 (n=15,13,19,1,2) | 2 (0 to 157) | 3 (0 to 419) | 0 (0 to 19) | 84 (NA to NA) | 2 (1 to 2) |
| Cycle 6 Day 1 (n=15,14,18,1,0) | 1 (0 to 90) | 2 (0 to 22) | 1 (0 to 5) | 27 (NA to NA) | NA (NA to NA) |
| FU 28 Day Visit (n=15,11,19,1,0) | 2 (0 to 113) | 2 (0 to 8) | 0 (0 to 7) | 7 (NA to NA) | NA (NA to NA) |
| FU 56 Day Visit (n=15,9,15,1,0) | 1 (0 to 215) | 3 (1 to 42) | 0 (0 to 2) | 14 (NA to NA) | NA (NA to NA) |
| FU 3 Month Visit (n=16,8,18,0,0) | 3 (0 to 469) | 1 (0 to 5) | 1 (0 to 6) | NA (NA to NA) | NA (NA to NA) |
| FU 6 Month Visit (n=15,13,17,1,0) | 2 (0 to 5929) | 1 (0 to 265) | 2 (0 to 96) | 51 (NA to NA) | NA (NA to NA) |
| FU 9 Month Visit (n=15,13,15,1,0) | 66 (0 to 15727) | 19 (1 to 728) | 29 (0 to 1153) | 74 (NA to NA) | NA (NA to NA) |
| FU 12 Month Visit (n=14,14,20,0,0) | 126 (4 to 1457) | 31 (0 to 2775) | 90 (2 to 1281) | NA (NA to NA) | NA (NA to NA) |
| FU 15 Month Visit (n=14,11,15,0,0) | 175 (14 to 2426) | 41 (3 to 6588) | 106 (29 to 500) | NA (NA to NA) | NA (NA to NA) |
| FU 18 Month Visit (n=13,14,15,0,0) | 175 (15 to 5871) | 82 (16 to 13749) | 189 (22 to 478) | NA (NA to NA) | NA (NA to NA) |
| FU 21 Month Visit (n=13,12,16,0,0) | 128 (27 to 10679) | 78 (9 to 314) | 149 (57 to 783) | NA (NA to NA) | NA (NA to NA) |
| FU 24 Month Visit(n=12, 4,16,0,0) | 238 (29 to 11989) | 110 (25 to 2225) | 232 (69 to 1343) | NA (NA to NA) | NA (NA to NA) |
Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
| percentage of participants | Part 1: Rituximab SC 1400 mg | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Rituximab SC 1000 mg | Part 1: No SC Dose Received |
|---|---|---|---|---|---|
| Cycle 5 Day 1 (n=15,1319,1,2) | 93.3 | 92.3 | 100.0 | 0.0 | 100.0 |
| Cycle 6 Day 1(n= 15,14,18,1,0) | 93.3 | 100.0 | 100.0 | 100.0 | NA |
| FU 28 Day Visit (n=15,11,19,1,0) | 93.3 | 100.0 | 100.0 | 100.0 | NA |
| FU 56 Day Visit (n=15,9,15,1,0) | 93.3 | 100.0 | 100.0 | 100.0 | NA |
| FU 3 Month Visit (n=16,8,18,0,0) | 93.8 | 100.0 | 100.0 | NA | NA |
| FU 6 Month Visit (n=15,13,17,1,0) | 86.7 | 92.3 | 94.1 | 100.0 | NA |
| FU 9 Month Visit (n=15,13,15,1,0) | 53.3 | 84.6 | 60.0 | 100.0 | NA |
| FU 12 Month Visit (n=14,14,20,0,0) | 28.6 | 85.7 | 45.0 | NA | NA |
| FU 15 Month Visit (n=14,11,15,0,0) | 35.7 | 54.5 | 40.0 | NA | NA |
| FU 18 Month Visit (n=13,14,15,0,0) | 30.8 | 50.0 | 26.7 | NA | NA |
| FU 21 Month Visit (n=13,12,16,0,0) | 30.8 | 50.0 | 18.8 | NA | NA |
| FU 24 Month Visit (n=12,14,16,0,0) | 25.0 | 21.4 | 18.8 | NA | NA |
CD 19 is a surface antigen (protein) present on B-lymphocytes.
| cells/μL | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Cycle 1 - Baseline (n=80,80) | 68905 (3996 to 277645) | 50565 (640 to 453292) |
| Cycle 2 - Pre-dose (n=71,74) | 338 (2 to 38252) | 253 (1 to 92469) |
| Cycle 2 - Post-dose (n=65, 66) | 163 (3 to 13026) | 168 (1 to 32615) |
| Cycle 2 Day 2 (n=54, 59) | 154 (6 to 10416) | 266 (0 to 40815) |
| Cycle 2 Day 3 (n=48, 54) | 87 (0 to 14769) | 125 (0 to 13229) |
| Cycle 3 Day 1 (n=67,68) | 12 (0 to 13118) | 8 (1 to 22392) |
| Cycle 4 Day 1 (n=71,69) | 4 (0 to 17827) | 4 (0 to 18672) |
| Cycle 5 Day 1 (n=68,67) | 2 (0 to 7146) | 2 (0 to 8542) |
| Cycle 6 Day 1 (n=71,64) | 3 (0 to 3612) | 3 (0 to 4234) |
| FU 28 Day Visit (n=66,64) | 2 (0 to 1299) | 2 (0 to 2749) |
| FU 56 Day Visit (n=63,67) | 2 (0 to 14331) | 2 (0 to 3539) |
| FU 3 Month Visit (n=67,67) | 2 (0 to 39037) | 2 (0 to 16413) |
| FU 6 Month Visit (n=60,69) | 3 (0 to 1356) | 3 (0 to 22630) |
| FU 9 Month Visit (n=65,64) | 35 (1 to 3776) | 30 (0 to 890) |
| FU 12 Month Visit (n=60,61) | 91 (4 to 9372) | 104 (1 to 1770) |
| FU 15 Month Visit (n=59,60) | 135 (6 to 16328) | 171 (5 to 9431) |
| FU 18 Month Visit (n=57,58) | 134 (5 to 15404) | 223 (3 to 22363) |
| FU 21 Month Visit (n=55,52) | 171 (5 to 7901) | 277 (5 to 39435) |
| FU 24 Month Visit (n=56,51) | 214 (0 to 78010) | 256 (6 to 10482) |
| Withdrawn/Termination (n=17,15) | 150 (2 to 90310) | 6 (0 to 35325) |
Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
| percentage of participants | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|
| Cycle 1 - Baseline (n=80,80)) | 0.0 | 0.0 |
| Cycle 2 - Pre-dose (n=71, 74) | 23.9 | 31.1 |
| Cycle 2 - Post-dose (n=65, 66) | 32.3 | 37.9 |
| Cycle 2 Day 2 (n=54, 59) | 35.2 | 30.5 |
| Cycle 2 Day 3 (n=48, 54) | 50.0 | 37.0 |
| Cycle 3 Day 1 (n=67,68) | 73.1 | 76.5 |
| Cycle 4 Day 1 (n=71,69) | 83.1 | 84.1 |
| Cycle 5 Day 1 (n=68,67) | 88.2 | 89.6 |
| Cycle 6 Day 1 (n=71,64) | 95.8 | 95.3 |
| FU 28 Day Visit (n=66,64) | 95.5 | 96.9 |
| FU 56 Day Visit (n=63,67) | 92.1 | 97.0 |
| FU 3 Month Visit (n=67,67) | 95.5 | 92.5 |
| FU 6 Month Visit (n=60,69) | 88.3 | 91.3 |
| FU 9 Month Visit (n=65,64) | 66.2 | 70.3 |
| FU 12 Month Visit (n=60,61) | 43.3 | 42.6 |
| FU 15 Month Visit (n=59,60) | 33.9 | 30.0 |
| FU 18 Month Visit (n=57,58) | 24.6 | 25.9 |
| FU 21 Month Visit (n=55,52) | 14.5 | 19.2 |
| FU 24 Month Visit (n=56,51) | 10.7 | 15.7 |
| Withdrawn/Termination (n=17,15) | 41.2 | 73.3 |
Collected over Adverse Events were recorded from the time of initiation of treatment until 28 days after completion of study treatment in Cycle 6.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Rituximab SC 1400 mg | — | 5/16 (31.3%) | 13/16 (81.3%) |
| Part 1: Rituximab SC 1600 mg | — | 8/17 (47.1%) | 16/17 (94.1%) |
| Part 1: Rituximab SC 1870 mg | — | 4/22 (18.2%) | 21/22 (95.5%) |
| Part 1: Rituximab SC 1000 mg | — | 1/1 (100%) | 1/1 (100%) |
| Part 1: No SC Dose Received | — | 3/8 (37.5%) | 7/8 (87.5%) |
| Part 2 : Rituximab IV 500 mg/m^2 | — | 35/89 (39.3%) | 80/89 (89.9%) |
| Part 2: Rituximab SC 1600 mg | — | 32/85 (37.6%) | 81/85 (95.3%) |
| Event | Part 1: Rituximab SC 1400 mg | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: Rituximab SC 1000 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/16 | 1/17 | 2/22 | 1/1 | 1/8 | 4/89 | 9/85 |
| Bone Marrow FailureBlood and lymphatic system disorders | 0/16 | 0/17 | 0/22 | 1/1 | 0/8 | 0/89 | 0/85 |
| ENTEROCOLITISGastrointestinal disorders | 0/16 | 0/17 | 0/22 | 1/1 | 0/8 | 0/89 | 0/85 |
| BACTERIAL SEPSISInfections and infestations | 0/16 | 0/17 | 0/22 | 1/1 | 0/8 | 0/89 | 0/85 |
| BRONCHITISInfections and infestations | 0/16 | 0/17 | 0/22 | 1/1 | 0/8 | 0/89 | 0/85 |
| AnaemiaBlood and lymphatic system disorders | 0/16 | 0/17 | 0/22 | 0/1 | 1/8 | 3/89 | 0/85 |
| PeumoniaInfections and infestations | 1/16 | 1/17 | 1/22 | 0/1 | 1/8 | 3/89 | 2/85 |
| PyrexiaGeneral disorders | 0/16 | 1/17 | 0/22 | 0/1 | 1/8 | 1/89 | 3/85 |
| HypersensitivityImmune system disorders | 0/16 | 0/17 | 0/22 | 0/1 | 1/8 | 0/89 | 0/85 |
| Tumor Lysis SyndromeMetabolism and nutrition disorders | 0/16 | 0/17 | 0/22 | 0/1 | 1/8 | 0/89 | 0/85 |
| Event | Part 1: Rituximab SC 1400 mg | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 1: Rituximab SC 1000 mg | Part 1: No SC Dose Received | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 7/16 | 8/17 | 9/22 | 1/1 | 3/8 | 51/89 | 54/85 |
| AnaemiaBlood and lymphatic system disorders | 2/16 | 2/17 | 1/22 | 1/1 | 2/8 | 21/89 | 11/85 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/16 | 3/17 | 2/22 | 1/1 | 1/8 | 25/89 | 20/85 |
| NauseaGastrointestinal disorders | 2/16 | 6/17 | 4/22 | 0/1 | 2/8 | 31/89 | 32/85 |
| LeukopeniaBlood and lymphatic system disorders | 3/16 | 6/17 | 0/22 | 0/1 | 1/8 | 15/89 | 16/85 |
| VomitingGastrointestinal disorders | 2/16 | 2/17 | 7/22 | 0/1 | 2/8 | 20/89 | 18/85 |
| PyrexiaGeneral disorders | 1/16 | 5/17 | 1/22 | 0/1 | 1/8 | 23/89 | 26/85 |
| Injection site erythemaGeneral disorders | 0/16 | 2/17 | 4/22 | 0/1 | 0/8 | 0/89 | 22/85 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 4/17 | 3/22 | 0/1 | 1/8 | 9/89 | 10/85 |
| SinusitisInfections and infestations | 0/16 | 2/17 | 4/22 | 0/1 | 0/8 | 5/89 | 3/85 |
Safety Analysis Population (SAP): all participants who received at least one dose of study medication whether prematurely withdrawn or not. In Part 2 two participants randomized to the rituximab SC 1600 mg arm were included in Rituximab IV 500 mg/m\^2 arm as they received only the first cycle of rituximab IV 375 mg/m\^2.
| Age, Continuous(years) | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 56.6 ± 10.13 | 60.4 ± 8.18 | 56.9 ± 6.79 | 58.7 ± 9.03 | 59.1 ± 8.87 | 58.8 ± 8.8 |
| Sex: Female, Male(Participants) | Part 1: Rituximab SC 1400 Milligrams (mg) | Part 1: Rituximab SC 1600 mg | Part 1: Rituximab SC 1870 mg | Part 2 : Rituximab IV 500 mg/m^2 | Part 2: Rituximab SC 1600 mg | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 2 | 7 | 36 | 25 | 76 |
| Male | 10 | 15 | 15 | 53 | 60 | 153 |
Ran from Apr 2011 to primary completion in May 2014, 36 months.
Results were first posted in Dec 2015, 1 year 7 months after primary completion.
Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 36 months is below that.
Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine
Leukemia, Lymphocytic, Chronic, B-Cell →